1,720,986 research outputs found
MSJ876701_supplemental_file – Supplemental material for Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets
No full textSupplemental material, MSJ876701_supplemental_file for Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets by Marcus W Koch, Jop Mostert, Bernard Uitdehaag and Gary Cutter in Multiple Sclerosis Journal</p
sj-docx-2-mso-10.1177_20552173221097580 - Supplemental material for Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis
No full textSupplemental material, sj-docx-2-mso-10.1177_20552173221097580 for Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis by Stephanie L. Silveira, Brenda Jeng, Gary Cutter and Robert W. Motl in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
sj-docx-1-mso-10.1177_20552173221097580 - Supplemental material for Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis
No full textSupplemental material, sj-docx-1-mso-10.1177_20552173221097580 for Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis by Stephanie L. Silveira, Brenda Jeng, Gary Cutter and Robert W. Motl in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
MSJ898591_supplemental_material – Supplemental material for New applications for independent activities of daily living in measuring disability in multiple sclerosis
No full textSupplemental material, MSJ898591_supplemental_material for New applications for independent activities of daily living in measuring disability in multiple sclerosis by Amber Salter, Robert J Fox, Tuula Tyry, Gary Cutter and Ruth Ann Marrie in Multiple Sclerosis Journal</p
MSJ845836_supplemental_material – Supplemental material for Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis
No full textSupplemental material, MSJ845836_supplemental_material for Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis by Kathryn C Fitzgerald, Amber Salter, Tuula Tyry, Robert J Fox, Gary Cutter and Ruth Ann Marrie in Multiple Sclerosis Journal</p
sj-docx-1-msj-10.1177_13524585211035740 – Supplemental material for Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial by Bianca Weinstock-Guttman, Robert Bermel, Gary Cutter, Mark S Freedman, Thomas P Leist, Xiaoye Ma, Deidre Kile, Bruno Musch, Anthony T Reder and Jerry S Wolinsky in Multiple Sclerosis Journal</p
sj-pdf-3-msj-10.1177_13524585211035740 – Supplemental material for Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
No full textSupplemental material, sj-pdf-3-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial by Bianca Weinstock-Guttman, Robert Bermel, Gary Cutter, Mark S Freedman, Thomas P Leist, Xiaoye Ma, Deidre Kile, Bruno Musch, Anthony T Reder and Jerry S Wolinsky in Multiple Sclerosis Journal</p
sj-pdf-2-msj-10.1177_13524585211035740 – Supplemental material for Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
No full textSupplemental material, sj-pdf-2-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial by Bianca Weinstock-Guttman, Robert Bermel, Gary Cutter, Mark S Freedman, Thomas P Leist, Xiaoye Ma, Deidre Kile, Bruno Musch, Anthony T Reder and Jerry S Wolinsky in Multiple Sclerosis Journal</p
sj-pdf-1-mso-10.1177_20552173231169463 - Supplemental material for Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
No full textSupplemental material, sj-pdf-1-mso-10.1177_20552173231169463 for Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial by Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Thijs Koster, Fred D Lublin, Jerry S Wolinsky, Henry McFarland, Steven Jacobson and Maria L Naylor in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
- …
